Join
Live feed
·
PRReleasevia Quantisnow
Windtree Therapeutics Inc. logo

Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference

ByQuantisnow·Wall Street's wire, on your screen.
WINT· Windtree Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WINT (Windtree Therapeutics Inc.) and more on Quantisnow.